Green Cross LabCell, a South Korea-based biopharmaceutical company, announced it will begin development of a COVID-19 treatment based on its anticancer therapy work using natural killer cells. Human clinical trials for the treatment are expected to begin in the second half of this year in the U.S. and South […]
Abstract The cellular immune responses elicited by an investigational vaccine against an emergent variant of influenza (H3N2v) are not fully understood. Twenty-five subjects, enrolled in an investigational influenza A/H3N2v vaccine study, who received two doses of vaccine 21 days apart, were included in a sub-study of cellular immune responses. […]
Abstract Seasonal influenza virus infections cause mild illness in healthy adults, as timely viral clearance is mediated by the functions of cytotoxic T cells. However, avian H5N1 influenza virus infections can result in prolonged and fatal illness across all age groups, which has been attributed to the overt and […]
RSVVW 2019 – A Global Conference on Novel RSV Preventive and Therapeutic Interventions.
RSV is a major cause of respiratory disease. This conference explored Novel RSV Preventive and Therapeutic Interventions, including antiviral, vaccines and monoclonal antibodies.
This was a global conference highlighting the challenge of the virus in LMICs
The conference was by all accounts a very successful and the organisers broadcast a free webinar on December 12th hosted by Prof. Louis Bont and Dr Natalie Mazur who gave a full summary of the highlights.
A replay of the webinar is available here and well worth a listen.
Further details of the conference itself are available here.
Slides from previous conferences on this cause of Respiratory Disease are here